vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and ENTEGRIS INC (ENTG). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $823.9M, roughly 1.4× ENTEGRIS INC). ENTEGRIS INC runs the higher net margin — 6.0% vs -24.1%, a 30.1% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs -3.1%). ENTEGRIS INC produced more free cash flow last quarter ($134.0M vs $46.0M). Over the past eight quarters, ENTEGRIS INC's revenue compounded faster (3.4% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Entegris, Inc. is a supplier of materials for the semiconductor and other high-tech industries. Entegris has approximately 8,000 employees throughout its global operations. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. The company’s corporate headquarters are in Billerica, Massachusetts.
ELAN vs ENTG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $823.9M |
| Net Profit | $-276.0M | $49.4M |
| Gross Margin | 51.5% | 43.8% |
| Operating Margin | -22.6% | 12.7% |
| Net Margin | -24.1% | 6.0% |
| Revenue YoY | 12.2% | -3.1% |
| Net Profit YoY | -3350.0% | -51.7% |
| EPS (diluted) | $-0.55 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $823.9M | ||
| Q3 25 | $1.1B | $807.1M | ||
| Q2 25 | $1.2B | $792.4M | ||
| Q1 25 | $1.2B | $773.2M | ||
| Q4 24 | $1.0B | $849.8M | ||
| Q3 24 | $1.0B | $807.7M | ||
| Q2 24 | $1.2B | $812.7M | ||
| Q1 24 | $1.2B | $771.0M |
| Q4 25 | $-276.0M | $49.4M | ||
| Q3 25 | $-34.0M | $70.5M | ||
| Q2 25 | $11.0M | $52.8M | ||
| Q1 25 | $67.0M | $62.9M | ||
| Q4 24 | $-8.0M | $102.2M | ||
| Q3 24 | $364.0M | $77.6M | ||
| Q2 24 | $-50.0M | $67.7M | ||
| Q1 24 | $32.0M | $45.3M |
| Q4 25 | 51.5% | 43.8% | ||
| Q3 25 | 53.4% | 43.5% | ||
| Q2 25 | 57.5% | 44.4% | ||
| Q1 25 | 57.3% | 46.1% | ||
| Q4 24 | 50.9% | 45.6% | ||
| Q3 24 | 52.2% | 46.0% | ||
| Q2 24 | 58.2% | 46.2% | ||
| Q1 24 | 57.3% | 45.6% |
| Q4 25 | -22.6% | 12.7% | ||
| Q3 25 | -4.4% | 15.2% | ||
| Q2 25 | 2.0% | 13.4% | ||
| Q1 25 | 5.0% | 15.8% | ||
| Q4 24 | -5.0% | 17.6% | ||
| Q3 24 | 54.3% | 16.9% | ||
| Q2 24 | -2.7% | 16.0% | ||
| Q1 24 | 1.0% | 15.3% |
| Q4 25 | -24.1% | 6.0% | ||
| Q3 25 | -3.0% | 8.7% | ||
| Q2 25 | 0.9% | 6.7% | ||
| Q1 25 | 5.6% | 8.1% | ||
| Q4 24 | -0.8% | 12.0% | ||
| Q3 24 | 35.3% | 9.6% | ||
| Q2 24 | -4.2% | 8.3% | ||
| Q1 24 | 2.7% | 5.9% |
| Q4 25 | $-0.55 | $0.33 | ||
| Q3 25 | $-0.07 | $0.46 | ||
| Q2 25 | $0.02 | $0.35 | ||
| Q1 25 | $0.13 | $0.41 | ||
| Q4 24 | $-0.01 | $0.67 | ||
| Q3 24 | $0.73 | $0.51 | ||
| Q2 24 | $-0.10 | $0.45 | ||
| Q1 24 | $0.06 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $360.4M |
| Total DebtLower is stronger | $3.9B | $3.7B |
| Stockholders' EquityBook value | $6.5B | $4.0B |
| Total Assets | $13.4B | $8.4B |
| Debt / EquityLower = less leverage | 0.60× | 0.94× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $360.4M | ||
| Q3 25 | $505.0M | $399.8M | ||
| Q2 25 | $539.0M | $376.8M | ||
| Q1 25 | $487.0M | $340.9M | ||
| Q4 24 | $468.0M | $329.2M | ||
| Q3 24 | $490.0M | $432.1M | ||
| Q2 24 | $416.0M | $320.0M | ||
| Q1 24 | $345.0M | $340.7M |
| Q4 25 | $3.9B | $3.7B | ||
| Q3 25 | $4.0B | $3.8B | ||
| Q2 25 | $4.1B | $4.0B | ||
| Q1 25 | $4.4B | $4.0B | ||
| Q4 24 | $4.3B | $4.0B | ||
| Q3 24 | $4.4B | $4.1B | ||
| Q2 24 | $5.7B | $4.1B | ||
| Q1 24 | $5.8B | $4.2B |
| Q4 25 | $6.5B | $4.0B | ||
| Q3 25 | $6.7B | $3.9B | ||
| Q2 25 | $6.8B | $3.8B | ||
| Q1 25 | $6.4B | $3.7B | ||
| Q4 24 | $6.1B | $3.7B | ||
| Q3 24 | $6.5B | $3.6B | ||
| Q2 24 | $5.9B | $3.5B | ||
| Q1 24 | $6.1B | $3.4B |
| Q4 25 | $13.4B | $8.4B | ||
| Q3 25 | $13.6B | $8.4B | ||
| Q2 25 | $13.7B | $8.4B | ||
| Q1 25 | $12.9B | $8.4B | ||
| Q4 24 | $12.6B | $8.4B | ||
| Q3 24 | $13.3B | $8.5B | ||
| Q2 24 | $13.8B | $8.3B | ||
| Q1 24 | $14.0B | $8.4B |
| Q4 25 | 0.60× | 0.94× | ||
| Q3 25 | 0.59× | 0.99× | ||
| Q2 25 | 0.61× | 1.05× | ||
| Q1 25 | 0.69× | 1.06× | ||
| Q4 24 | 0.70× | 1.08× | ||
| Q3 24 | 0.67× | 1.15× | ||
| Q2 24 | 0.96× | 1.18× | ||
| Q1 24 | 0.95× | 1.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $192.0M |
| Free Cash FlowOCF − Capex | $46.0M | $134.0M |
| FCF MarginFCF / Revenue | 4.0% | 16.3% |
| Capex IntensityCapex / Revenue | 5.4% | 7.0% |
| Cash ConversionOCF / Net Profit | — | 3.89× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $396.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $192.0M | ||
| Q3 25 | $219.0M | $249.5M | ||
| Q2 25 | $237.0M | $113.5M | ||
| Q1 25 | $-4.0M | $140.4M | ||
| Q4 24 | $177.0M | $176.1M | ||
| Q3 24 | $162.0M | $197.2M | ||
| Q2 24 | $200.0M | $111.2M | ||
| Q1 24 | $2.0M | $147.2M |
| Q4 25 | $46.0M | $134.0M | ||
| Q3 25 | $127.0M | $182.8M | ||
| Q2 25 | $180.0M | $47.0M | ||
| Q1 25 | $-69.0M | $32.4M | ||
| Q4 24 | $130.0M | $68.6M | ||
| Q3 24 | $120.0M | $115.0M | ||
| Q2 24 | $166.0M | $51.9M | ||
| Q1 24 | $-22.0M | $80.6M |
| Q4 25 | 4.0% | 16.3% | ||
| Q3 25 | 11.2% | 22.6% | ||
| Q2 25 | 14.5% | 5.9% | ||
| Q1 25 | -5.8% | 4.2% | ||
| Q4 24 | 12.7% | 8.1% | ||
| Q3 24 | 11.7% | 14.2% | ||
| Q2 24 | 14.0% | 6.4% | ||
| Q1 24 | -1.8% | 10.4% |
| Q4 25 | 5.4% | 7.0% | ||
| Q3 25 | 8.1% | 8.3% | ||
| Q2 25 | 4.6% | 8.4% | ||
| Q1 25 | 5.4% | 14.0% | ||
| Q4 24 | 4.6% | 12.7% | ||
| Q3 24 | 4.1% | 10.2% | ||
| Q2 24 | 2.9% | 7.3% | ||
| Q1 24 | 2.0% | 8.6% |
| Q4 25 | — | 3.89× | ||
| Q3 25 | — | 3.54× | ||
| Q2 25 | 21.55× | 2.15× | ||
| Q1 25 | -0.06× | 2.23× | ||
| Q4 24 | — | 1.72× | ||
| Q3 24 | 0.45× | 2.54× | ||
| Q2 24 | — | 1.64× | ||
| Q1 24 | 0.06× | 3.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
